Wednesday, May 22, 2013 Last update: 7:34 PM
Company Tech News as it Breaks

Mylan Inc.

News articles for Mylan Inc.:

Tuesday, May 21, 2013

Friday, May 17, 2013

  • Mylan Launches Generic Tricor® Tablets
    PITTSBURGH, May 17, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application ... read more

Wednesday, May 15, 2013

  • Mylan Launches Generic Zomig® Tablets
    PITTSBURGH, May 15, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Zolmitriptan Tablets, 2.5 mg and 5 mg. This product ... read more

Thursday, May 2, 2013

Tuesday, April 30, 2013

Monday, April 22, 2013

Tuesday, April 9, 2013

Wednesday, April 3, 2013

  • Mylan Launches First Generic Version of Zovirax® Ointment
    PITTSBURGH, April 3, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acyclovir Ointment USP, 5%. This product is the first generic ... read more

Monday, March 18, 2013

  • Mylan Launches Generic Version of Xopenex® Inhalation Solution
    PITTSBURGH, March 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 ... read more

Wednesday, March 13, 2013

  • Mylan Announces Fortamet® Settlement Agreement
    PITTSBURGH, March 13, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with Shionogi Inc. and Andrx that will resolve patent litigation related to Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg. This ... read more

Monday, March 4, 2013

  • Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2012
    PITTSBURGH, March 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec. 31, 2012, as filed with the U.S. Securities and Exchange Commission on Feb. 28, 2013, is available through ... read more

Wednesday, February 27, 2013

Monday, February 25, 2013

  • Mylan Launches Generic Antara® Capsules
    PITTSBURGH, Feb. 25, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has begun shipping Fenofibrate Capsules USP, 43 mg and 130 mg. This product is the generic version of Lupin Atlantis Holdings, S.A.'s Antara(®) Capsules, which are indicated as an adjunct ... read more

Saturday, February 23, 2013

Wednesday, February 20, 2013

Wednesday, February 13, 2013

Monday, February 11, 2013

  • Mylan Appoints Melina Higgins and Rajiv Malik to Board of Directors
    PITTSBURGH, Feb. 11, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its board of directors has voted unanimously to appoint Melina Higgins, a former partner at Goldman, Sachs & Co., and Rajiv Malik, currently Mylan's president, to Mylan's board. With the appointments of Higgins and ... read more

Thursday, January 31, 2013